ImmunoVaccine Technologies Partners with Scancell to Advance DNA Vaccine Delivery
News Aug 06, 2009
ImmunoVaccine Technologies Inc. (IVT) has signed an agreement with UK-based Scancell Ltd., which is developing therapeutic cancer and infectious disease vaccines. This research agreement will explore the potential of using IVT's DepoVax™ delivery system for Scancell's novel ImmunoBody® DNA vaccines.
"Scancell is developing an exciting DNA vaccine technology and we are delighted to enter into this collaboration," remarked Dr. Marc Mansour, vice president of R D at IVT. "Our DepoVax™ technology has the potential to better deliver DNA vaccines to draining lymph nodes to produce high levels of immune response using conventional immunization techniques."
"IVT's DepoVax™ represents a potentially attractive future delivery system for our ImmunoBody® DNA vaccines, especially those for certain infectious diseases where alternative delivery methods such as electroporation may be less suitable." commented David Evans, chairman of Scancell.
DNA-based vaccines have gained popularity due to promising results reported the clinic, their relative ease of manufacture and potential for enhanced stability. There is currently a need for simple alternative methods of delivering DNA vaccines.
DepoVax™ is a vaccine-enhancement and delivery platform comprised of liposomes, adjuvants and oil. DepoVax™ enhances the immunogenicity of antigens in general, and can be used to enhance the delivery of polynucleotide-based antigens and SiRNA to lymph nodes. IVT has proven its scale-up capabilities at a contract manufacturing plant, making DepoVax™ amenable to commercialization.